Search research articles
Contact Us
Filters
Showing results (1-10 of 142) with videos related to
Page
of 15
Sort By:
Molecular Therapy Oncolytics
|
April 28, 2016
Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?
Benjamin Ruf, Ulrich M Lauer
Future Oncology (London, England)
|
July 12, 2022
Oncolytic viruses: challenges and considerations in an evolving clinical landscape
Ulrich M Lauer, Julia Beil
Oncolytic Virotherapy
|
August 12, 2016
Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy
Eike Binz, Ulrich M Lauer
Oncogene
|
March 28, 2025
Deciphering permissivity of human tumor ecosystems to oncolytic viruses
Benjamin Schoeps, Ulrich M Lauer, Knut Elbers
Oncolytic Virotherapy
|
September 21, 2018
Three-dimensional tumor cell cultures employed in virotherapy research
Linus D Kloker, Can Yurttas, Ulrich M Lauer
Methods in Molecular Biology (Clifton, N.J.)
|
November 8, 2011
Preclinical testing of virotherapeutics for primary and secondary tumors of the liver
Martina Zimmermann, Timo Weiland, Michael Bitzer, et al.
Gynecologic Oncology
|
July 19, 2011
Oncolytic virotherapy of breast cancer
Andreas D Hartkopf, Tanja Fehm, Diethelm Wallwiener, et al.
Expert Opinion on Biological Therapy
|
August 6, 2009
Emerging gene-directed anti-tumor strategies against human hepatoblastoma
Steven W Warmann, Jörg Fuchs, Michael Bitzer, et al.
The Journal of Gene Medicine
|
June 26, 2003
Sendai virus vectors as an emerging negative-strand RNA viral vector system
Michael Bitzer, Sorin Armeanu, Ulrich M Lauer, et al.
Frontiers in Oncology
|
January 10, 2022
Clinical Trials of Oncolytic Viruses in Breast Cancer
Mary E Carter, André Koch, Ulrich M Lauer, et al.
Page
of 15
Search research articles
Search
Showing results (1-10 of 142) with videos related to
Sort By:
Page
of 15
Molecular Therapy Oncolytics
|
April 28, 2016
Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?
Benjamin Ruf, Ulrich M Lauer
Future Oncology (London, England)
|
July 12, 2022
Oncolytic viruses: challenges and considerations in an evolving clinical landscape
Ulrich M Lauer, Julia Beil
Oncolytic Virotherapy
|
August 12, 2016
Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy
Eike Binz, Ulrich M Lauer
Oncogene
|
March 28, 2025
Deciphering permissivity of human tumor ecosystems to oncolytic viruses
Benjamin Schoeps, Ulrich M Lauer, Knut Elbers
Oncolytic Virotherapy
|
September 21, 2018
Three-dimensional tumor cell cultures employed in virotherapy research
Linus D Kloker, Can Yurttas, Ulrich M Lauer
Methods in Molecular Biology (Clifton, N.J.)
|
November 8, 2011
Preclinical testing of virotherapeutics for primary and secondary tumors of the liver
Martina Zimmermann, Timo Weiland, Michael Bitzer, et al.
Gynecologic Oncology
|
July 19, 2011
Oncolytic virotherapy of breast cancer
Andreas D Hartkopf, Tanja Fehm, Diethelm Wallwiener, et al.
Expert Opinion on Biological Therapy
|
August 6, 2009
Emerging gene-directed anti-tumor strategies against human hepatoblastoma
Steven W Warmann, Jörg Fuchs, Michael Bitzer, et al.
The Journal of Gene Medicine
|
June 26, 2003
Sendai virus vectors as an emerging negative-strand RNA viral vector system
Michael Bitzer, Sorin Armeanu, Ulrich M Lauer, et al.
Frontiers in Oncology
|
January 10, 2022
Clinical Trials of Oncolytic Viruses in Breast Cancer
Mary E Carter, André Koch, Ulrich M Lauer, et al.
Page
of 15